to study search History No further version available for comparison

Association between potassium levels, variability and supplementation and in-hospital mortality

Organizational Data

DRKS-ID:
DRKS00016411
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2019-01-11
Last update in DRKS:
2019-01-11
Registration type:
Retrospective

Acronym/abbreviation of the study

KaliMo

URL of the study

No Entry

Brief summary in lay language

Current guidelines do not make a clear statement about how precise potassium target ranges should be set in intensive care patients and from when potassium substitution should take place. Recent studies on patients after myocardial infarction give evidence of reduced mortality in low-normal potassium ranges. In addition, the variability of potassium concentrations in the blood appears to have an influence. The aim of this retrospective data analysis is to find a potassium range associated with the lowest mortality rate in intensive care patients, as well as to study the influence of variability. Also of interest is the role of potassium substitution and potassium substitution additively to insulin therapy.

Brief summary in scientific language

Potassium homeostasis is regulated within extracellular concentrations between 3.5 and 5.0 mmol/l. This is of importance for physiologic processes, such as the negative resting membrane potential and consequently neuromuscular and cardiac excitability. Severe hyperkalemia is associated with ventricular arrhythmia, bradycardia and cardiac arrest. Hypo- and hyperkalemia compared to normal rages are associated with an increased complication rate and mortality risk. In patients with myocardial infarction the American College of Cardiology/American Heart Association (ACC/AHA) Guidelines suggest to elevate potassium levels to 4.0-5.0mmol/l to reduce the risk of ventricular fibrillation. After cardiac and thoracic surgery, guidelines recommend to correct hypokalemia to 4.5-5.5mmol/l to prevent atrial fibrillation, although they emphasize that this suggestion has never been scientifically confirmed. In summary, previous guidelines recommend potassium levels rather in the upper normokalemic range. However, a recent systematic review found evidence that potassium levels above 4.5mmol/l may be adversely associated with survival in patients with myocardial infarction. Increased mortality has been shown for hyperkalemia in ICU patients. To our knowledge, there is no valid guideline available regarding potassium target ranges and supplementation in ICU patients. The purpose of this retrospective study was to analyze mean potassium levels as well as potassium variability and their association with mortality in a general ICU population. Additionally, we investigated the association of potassium supplementation with mortality.

Health condition or problem studied

ICD10:
E87 - Other disorders of fluid, electrolyte and acid-base balance
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
All intensive care patients in the inclusion interval will be considered. All clinical evaluated potassium values ​​of patients during their hospital stay were recorded. The hospital routine specifies the frequency and the interval of measurments. Performing the analyses, the subdivision is based on potassium mean values ​​and on the standard deviation per patient.
Arm 2:
Division in patients of different potassium variability

Endpoints

Primary outcome:
in-Hospital mortality dependent on mean potassium levels
Secondary outcome:
in-Hospital mortality dependent on potassium variability in-Hospital mortality dependent on potassium substitution

Study Design

Purpose:
Other
Retrospective/prospective:
No Entry
Study type:
Non-interventional
Longitudinal/cross-sectional:
No Entry
Study type non-interventional:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Monocenter study
Recruitment location(s):
  • University medical center Charité Universitätsmedizin Berlin Berlin

Recruitment period and number of participants

Planned study start date:
No Entry
Actual study start date:
2018-11-30
Planned study completion date:
No Entry
Actual Study Completion Date:
2018-12-31
Target Sample Size:
50000
Final Sample Size:
53248

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
no maximum age
Additional Inclusion Criteria:
ICU Patient at Charité University Hospital from 2006 to 2018

Exclusion Criteria

less than 2 potassium values during stay

Addresses

Primary Sponsor

Address:
Charité Campus Virchow-Klinikum
Augustenburger Platz 1
13353 Berlin
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.charite.de
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Charité - Universitätsmedizin BerlinKlinik für Anästhesiologie m.S. operative Intensivmedizin
Dr. med. Tobias Wollersheim
Augustenburger Platz 1
13353 Berlin
Germany
Telephone:
030450651808
Fax:
030450551909
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.charite.de

Contact for Public Queries

Address:
Charité - Universitätsmedizin BerlinKlinik für Anästhesiologie m.S. operative Intensivmedizin
Dr. med. Tobias Wollersheim
Augustenburger Platz 1
13353 Berlin
Germany
Telephone:
030450651808
Fax:
030450551909
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.charite.de

Principal Investigator

Address:
Charité - Universitätsmedizin BerlinKlinik für Anästhesiologie m.S. operative Intensivmedizin
Dr. med. Tobias Wollersheim
Augustenburger Platz 1
13353 Berlin
Germany
Telephone:
030450651808
Fax:
030450551909
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.charite.de

Sources of Monetary or Material Support

Institutional budget, no external funding (budget of sponsor/PI)

Address:
Charité - Universitätsmedizin BerlinKlinik für Anästhesiologie m.S. operative Intensivmedizin
Augustenburger Platz 1
13353 Berlin
Germany
Telephone:
030450651808
Fax:
030450551909
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.charite.de

Ethics Committee

Address Ethics Committee

Address:
Ethikkommission der Charité – Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin
Germany
Telephone:
(+49)30-450517222
Fax:
(+49)30-450517952
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2018-09-03
Ethics committee number:
EA2/187/18
Vote of the Ethics Committee:
Approved
Date of the vote:
2018-11-30

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No Entry
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry